# Application of Amyloid PET in Cerebral Amyloid Angiopathy

Study · id `cardio:ct-nct03542656` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03542656](<https://clinicaltrials.gov/study/NCT03542656>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03542656

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.

## Technical summary

Registry record NCT03542656. Allocation not applicable; no masking; primary purpose diagnostic. Start 2014-09-11 (actual); primary completion 2016-02-17 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Phase 3
- Enrolled: 160 participants (enrolled count; ClinicalTrials.gov record NCT03542656, source copy `cardio:ctgov-nct03542656-2019-05-30`, retrieved 2026-10-26)
- Started: 2014-09-11 (actual) (ClinicalTrials.gov record NCT03542656, source copy `cardio:ctgov-nct03542656-2019-05-30`, retrieved 2026-10-26)
- Primary completion: 2016-02-17 (actual) (ClinicalTrials.gov record NCT03542656, source copy `cardio:ctgov-nct03542656-2019-05-30`, retrieved 2026-10-26)
- Completion: 2018-03-22 (actual) (ClinicalTrials.gov record NCT03542656, source copy `cardio:ctgov-nct03542656-2019-05-30`, retrieved 2026-10-26)
- Countries: Taiwan (ClinicalTrials.gov record NCT03542656, source copy `cardio:ctgov-nct03542656-2019-05-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03542656-2019-05-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Application of Amyloid PET in Cerebral Amyloid Angiopathy
- Acronym: CAA
- Condition: Cerebral Amyloid Angiopathy
- Condition: Intracranial Hemorrhages
- Condition: Alzheimer Disease
- Intervention (Drug): amyloid PET
- Lead sponsor: National Taiwan University Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Bleeding in the brain (intracerebral hemorrhage) (`cardio:intracerebral-hemorrhage`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: National Taiwan University Hospital (`cardio:org-national-taiwan-university-hospital`)

## Provenance

Content hash: 559a406d6bfdc956676629348e892500578d03e736eb4a3f9733fc8ee5ed1b4b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
